Search

for
Search:

Did you mean Immune Checkpoint Inhibitors?

Glossary Immune Checkpoint Inhibitors

block proteins that prevent immune cells from attacking cancer

Immune Checkpoint Inhibitors (ICIs) are a type of cancer treatment that work by blocking proteins used by cancer cells to evade the immune system. By inhibiting these checkpoints, such as PD-1, PD-L1, and CTLA-4, ICIs enable the immune system to better recognize and attack cancer cells.

Related Terms

Research

5 / 1000+ results

research Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors

87 citations , December 2016 in “British journal of dermatology/British journal of dermatology, Supplement”

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

research Cutaneous manifestations associated with immune checkpoint inhibitors

14 citations , February 2023 in “Frontiers in immunology”

This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.

Immune Checkpoint Inhibitor-Related Alopecia: Insight into the Pathophysiology Using Non-Invasive Diagnostic Techniques

research Immune checkpoint inhibitor‐related alopecia: Insight into the pathophysiology utilizing non‐invasive diagnostic techniques

6 citations , January 2019 in “Journal of dermatology”

This letter to the editor discusses immune checkpoint inhibitor-related alopecia and insights into its pathophysiology using non-invasive diagnostic techniques, but reports no new clinical results.

research [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review

6 citations , March 2022 in “Actas Dermo-Sifiliográficas”

This review discusses the characteristics and management of cutaneous immune-related adverse events from immune checkpoint inhibitors and notes their potential association with a favorable cancer treatment response.

research Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors

3 citations , July 2022 in “European Journal of Dermatology”

In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.

View more "immune-checkpoint inhibitor" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →